Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene

Journal of Cellular Physiology

Volumn 188, Issue 1, 2001, Pages 98-105

  Guan, Baoxiang ^a   Yue, Ping ^a   Clayman, Gary L ^a   Sun, Shi Yong ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DACTINOMYCIN; FAS ANTIGEN; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, NORTHERN; DACTINOMYCIN; DNA DAMAGE; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; MEMBRANE GLYCOPROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 0035008833     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.1101     Document Type: Article

References (52)

1. Ashkenazi A, Dixit VM. 1998. Death receptors: signaling and modulation. Science 281:1305-1308.
2. Ashkenazi A, Dixit VM. 1999. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260.
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162.
4. Bates S, Vousden KH. 1999. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28-37.
5. Buckbinder L, Talbottm R, Velasco-Miguelm S, Takenakam I, Faham B, Seizingerm B R, Kley N. 1995. Induction of growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649.
6. Chan H, Bartos DP, Owen-Schaub LB. 1999. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 19:2098-2108.
7. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. 1997. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813-820.
8. Degli-Esposti MA. 1999. To die or not to die-the quest of the TRAIL receptors. J Leukoc Biol 65:535-542.
9. El-Deiry WS. 1998. Regulation of p53 downstream genes. Semi Cancer Biol 8:345-357.
10. El-Deiry WS, Takashi T, Velculescu VE, Levy DB. Parsons R, Trent JM, Lin D, Mercer WE, Kanzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
11. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
12. Frederick MJ, Holton PR, Hudson M, Wang M, Clayman GL. 1999. Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death. Clin Cancer Res 5:361-369.
13. French LE, Tschopp J. 1999. The TRAIL to selective tumor death. Nat Med 5:146-147.
14. Fricker J. 1999. On the TRAIL to a new cancer therapy. Mol Med Today 5:p374.
15. Fritsche M, Haessler C, Brandner G. 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318.
16. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. 2000. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 20:205-212.
17. Gottlieb TM, Oren M. 1998. p53 and apoptosis. Cancer Biol 8:359-368.
18. Isaacs WB, Carter BS, Ewing CM. 1991. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720.
19. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, Smith JR. 1994. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 11:59-64.
20. Juven T, Barak Y, Zauberman A, George DL, Oren M. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
21. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597.
22. Kim K, Fisher MJ, Xu SQ, El-Deiry W. 2000. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6:335-346.
23. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
24. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. 1994. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54:3662-3667.
25. Meng R, McDonald ER 3rd, Sheikh MS, Fornace AJ Jr., El-Deiry WS. 2000. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 1:130-144.
26. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. 1994. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391-3395.
27. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila I, Mulshine JL, Minna JD, Gazdar AF. 1992. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180.
28. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell 80:293-299.
29. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188:2033-4205.
30. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. 2000. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60:847-853.
31. Nagata S. 1997. Apoptosis by death factor. Cell 88:355-365.
32. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R. 1995. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-3040.
33. Ozoren N, Fisher MJ, Kim K, Liu CX, Genin A, Shifman Y, Dicker DT, Spinner NB, Lisitsyn NA, El-Deiry WS. 2000. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 16:917-925.
34. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276:111-113.
35. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690.
36. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. 1997. Characterization of two receptors for TRAIL. FEBS Lett 416:329-334.
37. Sheikh MS, Burns T F, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ Jr., El-Deiry WS. 1998. p53-dependent and -independent regulation of the death receptor Killer/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58:1593-1598.
38. Sheikh MS, Fornace AJ Jr. 2000. Role of p53 family member in apoptosis. J Cell Physiol 182:171-181.
39. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. 1994. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9:3407-3415.
40. Sheikh MS, Huang Y, Fernandez-Sales EA, El-Deiry WS, Friess H, Amundson S, Yin J, Meltzer SJ, Holbrook NJ, Fornace AJ Jr. 1999. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 18:4153-4159.
41. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821.
42. Amegan EST Program. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
43. Song Z, Steller H. 1999. Death by design: mechanism and control of apoptosis. Trends Cell Biol 9:M49-52.
44. Sun S-Y, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, Heyman RA, Chandraratna RAS, Shudo K, Hong WK, Lotan R. 2000. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 6:1563-1573.
45. Sun S-Y, Yue P, Shroot B, Michel S, Mawson MI, Lamph WW, Heyman RA, Teng M, Chandraratna RAS, Shudo K, Hong WK, Lotan R. 1997. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 57:4931-4939.
46. Sun S-Y, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, Lotan R. 1999. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 18:2357-2365.
47. Takimoto R, El-Deiry WS. 2000. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-bindingsite. Oncogene 19:1735-1743.
48. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
49. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
50. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17:141-143.
51. Wu L, Levine AJ. 1997. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med 3:441-451.
52. Xu SQ, El-Deiry WS. 2000. p21 (WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269:179-190.